inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia
2003-10-01 Jean-Loup Huret Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
Treatment related myelodysplasia (t-MDS) or acute myeloid leukaemias (t-AML)
Note
The study included 48 cases; t-MDS without progression to AML accounted for 8%, t-MDS with progression to AML for 13% and t-AML for the remaining 79% the AML subtype was M4eo in 83%, M2 in 14%; no case of acute lymphoblastic leukaemia
Epidemiology
inv(16)(p13q22) was found in 9% of t-MDS/t-AML; sex ratio: 18M/30F
Clinics
Age at diagnosis of the primary disease 43 yrs (range 6-75); age at diagnosis of the t-MDS/t-AML: 48 yrs (range 13-77). Median interval was short: 22 mths (range: 8-533). Primary disease was a solid tumor in 71% of cases (in particular breast cancer, sarcoma, cancer of the ovary) and a hematologic malignancy in 27%, treatment was radiotherapy (21%, a relatively high proportion compared to other groups), chemotherapy (29%), or both (50%). Treatment included topoisomerase II inhibitors in 60% of cases and alkylating agents in 63%.
Prognosis
Patients under 55 yrs of age had better outcome. Median survival was 29 mths, with 45% of patients surviving at 5 yrs, the best survival among subgroups of treatment related leukemias with a balanced chromosome aberration (patients with 11q23 rearrangement, 3q21q26 rearrangement, 12p13 rearrangement, t(9;22), t(8;16), or a 21q22 rearangement)). Patients with t(15;17) had similar median survival, but less long term survivors.
Genes Involved and Proteins
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 31817911 | 2019 | Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription. | 150 |
| 34440157 | 2021 | How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. | 123 |
| 38061017 | 2023 | Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia-initiating CBFB::MYH11 oncofusion protein. | 112 |
| 32831296 | 2020 | CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. | 93 |
| 36874378 | 2023 | Therapy-related core binding factor acute myeloid leukemia. | 86 |
| 29755956 | 2018 | Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia. | 81 |
| 34804441 | 2021 | Gastrointestinal Myeloid Sarcoma a Case Presentation and Review of the Literature. | 80 |
| 27798625 | 2016 | The genomic landscape of core-binding factor acute myeloid leukemias. | 79 |
| 37019972 | 2023 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | 71 |
| 34686664 | 2021 | Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. | 70 |
| 34336831 | 2021 | CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML. | 67 |
| 20589720 | 2010 | RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1). | 57 |
| 35973983 | 2022 | Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia. | 52 |
| 17185462 | 2007 | CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus. | 50 |
| 22160378 | 2012 | KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. | 50 |
| 36011278 | 2022 | PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia. | 49 |
| 20007544 | 2010 | Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11. | 48 |
| 36442087 | 2022 | Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. | 47 |
| 32929473 | 2020 | RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development. | 47 |
| 31624376 | 2020 | Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice. | 46 |
| 15044690 | 2004 | Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. | 44 |
| 30742053 | 2019 | IL1RL1 is dynamically expressed on Cbfb-MYH11(+) leukemia stem cells and promotes cell survival. | 43 |
| 34771519 | 2021 | CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. | 42 |
| 29018080 | 2017 | Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11. | 41 |
| 31896782 | 2020 | The clinical mutatome of core binding factor leukemia. | 40 |
| 28030795 | 2017 | AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis. | 40 |
| 36452349 | 2022 | Analytical study of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1(p210) , and KMT2-MLLT3 in Mexican children with acute myeloid leukemia: A multicenter study of the Mexican interinstitutional group for the identification of the causes of childhood leukemia (MIGICCL). | 39 |
| 21638519 | 2011 | CBFB and MYH11 in inv(16)(p13q22) of acute myeloid leukemia displaying close spatial proximity in interphase nuclei of human hematopoietic stem cells. | 39 |
| 38427924 | 2024 | Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). | 37 |
| 35794567 | 2022 | Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD-positive acute myeloid leukemia. | 37 |
| 34547772 | 2021 | CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. | 35 |
| 25742748 | 2015 | Runx1 is required for hematopoietic defects and leukemogenesis in Cbfb-MYH11 knock-in mice. | 34 |
| 38493200 | 2024 | Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies. | 34 |
| 31899799 | 2020 | Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. | 33 |
| 25266220 | 2014 | CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia. | 33 |
| 35445594 | 2022 | Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 Fusions. | 31 |
| 35497938 | 2022 | Therapy-related acute myeloid leukemia: A case series. | 30 |
| 33204999 | 2020 | Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1. | 15 |
| 37225965 | 2023 | Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing. | 14 |
| 33816105 | 2021 | Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion. | 13 |
| 23236551 | 2013 | Acute myeloid leukemia with cryptic CBFB-MYH11 type D. | 10 |
| 34512985 | 2021 | Abnormal eosinophils with immature eosinophilic granules in chronic myeloid leukemia in accelerated phase. | 2 |
| 38153768 | 2023 | CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia. | 0 |
| 11561156 | 2001 | Function of the inv(16) fusion gene CBFB-MYH11. | 0 |
| 34183780 | 2021 | Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11. | 0 |
| 31671434 | 2020 | Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen. | 0 |
| 28906004 | 2017 | Acute myeloid leukaemia (FAB AML-M4Eo) with cryptic insertion of cbfb resulting in cbfb-Myh11 fusion. | 0 |
| 38388794 | 2024 | Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11. | 0 |
| 36653696 | 2023 | Comprehensive molecular understanding of pediatric acute myeloid leukemia. | 0 |
| 32202250 | 2021 | Detection of del(16q) using the CBFB-MYH11 translocation dual fusion probe. | 0 |
| 31353165 | 2020 | Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22). | 0 |
| 32588434 | 2021 | The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis. | 0 |
| 11241787 | 2001 | Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR. | 0 |
| 35128634 | 2022 | TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event. | 0 |
| 36039018 | 2022 | Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia. | 0 |
| 15156186 | 2004 | Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. | 0 |
| 20513535 | 2010 | Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review. | 0 |
| 22032582 | 2011 | Core-binding factor acute myeloid leukemia. | 0 |
| 28299658 | 2017 | Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders. | 0 |
| 8929537 | 1996 | Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. | 0 |
| 30919505 | 2019 | Measurable residual disease testing for personalized treatment of acute myeloid leukemia. | 0 |
| 28299661 | 2017 | Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia. | 0 |
| 8751466 | 1996 | The gene product of CBFB-MYH11. | 0 |
| 12239155 | 2002 | Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. | 0 |
| 8585960 | 1996 | Transforming properties of the leukemic inv(16) fusion gene CBFB-MYH11. | 0 |
| 7795233 | 1995 | RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts. | 0 |
| 31721036 | 2020 | Mature neutrophils with Auer rod bundles in CBFB-MYH11-positive acute myeloid leukemia. | 0 |
| 24002588 | 2014 | CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. | 0 |
| 17287858 | 2007 | Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. | 0 |
| 30006258 | 2018 | Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician. | 0 |
| 38801226 | 2024 | Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. | 0 |
| 19215788 | 2009 | Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits. | 0 |
| 25348871 | 2015 | Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. | 0 |
| 27650511 | 2018 | Monitoring of post-transplant CBFB-MYH11 as minimal residual disease, rather than KIT mutations, can predict relapse after allogeneic haematopoietic cell transplantation in adults with inv(16) acute myeloid leukaemia. | 0 |
| 25635758 | 2015 | Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. | 0 |
| 21281226 | 2011 | De novo acute myeloid leukemia with Philadelphia chromosome (BCR-ABL) and inversion 16 (CBFB-MYH11): report of two cases and review of the literature. | 0 |
| 27468869 | 2016 | Incidence of preleukemic fusion genes in healthy subjects. | 0 |
| 7577615 | 1995 | Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. | 0 |
| 17052753 | 2007 | Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients. | 0 |
| 39803562 | 2024 | Loss of the Inv(16) Oncogene CBFB::MYH11 Eliminates Leukemia from the Blood and Spleen, but not the Bone Marrow. | 0 |
| 37102302 | 2023 | TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia. | 0 |
| 35622005 | 2022 | AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome. | 0 |
| 38654658 | 2024 | Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. | 0 |
| 12139724 | 2002 | Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion. | 0 |
| 38220149 | 2023 | [Acute myeloid leukemia with type I CBFB::MYH11 fusion gene not detected by screening test for leukemia-related chimeric genes]. | 0 |
| 33162510 | 2020 | [Clinical significance of MRD in AML]. | 0 |
| 28475434 | 2017 | Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. | 0 |
| 38084551 | 2023 | Therapy-related acute myeloid leukemia with CBFB/MYH11 in a patient with ovarian cancer after exposure to chemotherapy. | 0 |
| 8630430 | 1996 | Novel CBFB-MYH11 fusion transcripts or reverse transcription-polymerase chain reaction artifacts? | 0 |
| 12788791 | 2003 | Rapid identification of CBFB-MYH11-positive acute myeloid leukemia (AML) cases by one single MYH11 real-time RT-PCR. | 0 |
| 27512765 | 2016 | Wilms’ Tumor Gene (WT1) Expression and Minimal Residual Disease in Acute Myeloid Leukemia. | 0 |
| 16502584 | 2006 | Diagnosis and monitoring of CBFB-MYH11-positive acute myeloid leukemia by qualitative and quantitative RT-PCR. | 0 |
| 35184217 | 2022 | 3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. | 0 |
| 20625124 | 2010 | Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia. | 0 |
| 31399807 | 2019 | BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis. | 0 |
| 16193088 | 2005 | Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR. | 0 |
| 23878140 | 2013 | Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia. | 0 |
| 35613501 | 2022 | Jumping translocation involving chromosome 13q in a patient with Crohn's Disease and inv(16)(p13.1q22)/CBFB-MYH11 acute myeloid leukemia. | 0 |
| 19901261 | 2010 | Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. | 0 |
| 29517504 | 2018 | Somatic Mutations and Intratumoral Heterogeneity of MYH11 Gene in Gastric and Colorectal Cancers. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 11921273 | 2002 | Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. | Andersen MK et al |
Summary
Fusion gene
CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) M ins(16)(q22p13p13) ins(16;16)(q22;p13p13) inv(16)(p13q22) t(16;16)(p13;q22)|CBFB/MYH11 CBFB (16q22.1) MYH11 (16p13.11) TIC
Note
This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002.
inv(16)(p13q22) CBFB/MYH11 and t(16;16)(p13;q22) CBFB/MYH11 Top: inv(16) FISH and diagram - Courtesy Hossein Mossafa; Middle Left: first row: inv(16)(p13q22) G-banding - Courtesy Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic Services; second row - Courtesy Hossein Mossafa; Middle Right: t(16;16)(p13;q22) u2013 Courtesy Adriana Zamecnikova; Bottom: Fluorescence in situ hybridization with the Vysis LSI CBFB break apart probe (Abbott Molecular, US) showing disruption of the gene as a result of (A) inv(16) and (B) its translocation to der(16) as a result of t(16;16) u2013 Courtesy Adriana Zamecnikova - Courtesy Adriana Zamecnikova.
Citation
Jean-Loup Huret
inv(16)(p13q22) CBFB/MYH11 in treatment related leukemia
Atlas Genet Cytogenet Oncol Haematol. 2003-10-01
Online version: http://atlasgeneticsoncology.org/haematological/1297/inv(16)(p13q22)
